The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2
Open accessAbstract
Clinical application of doxorubicin (DOX), an anthracycline antibiotic with potent anti- tumor effects, is limited because of its cardiotoxicity. However, its pathogenesis is still not entirely understood. The aim of this paper was to explore the mechanisms and new drug targets to treat DOX-induced cardiotoxicity. The in vitro model on H9C2 cells and the in vivo models on rats and mice were developed. The results showed that DOX markedly decreased H9C2 cell viability, increased the levels of CK, LDH, caused histopathological and ECG changes in rats and mice, and triggered myocardial oxidative damage via adjusting the levels of intracellular ROS, MDA, SOD, GSH and GSH-Px. Total of 18 differentially expressed microRNAs in rat heart tissue caused by DOX were screened out using microRNA microarray assay, especially showing that miR-140-5p was significantly increased by DOX which was selected as the target miRNA. Double-luciferase reporter assay showed that miR-140-5p directly targeted Nrf2 and Sirt2, as a result of affecting the expression levels of HO-1, NQO1, Gst, GCLM, Keap1 and FOXO3a, and thereby increasing DOX-caused myocardial oxidative damage. In addition, the levels of intracellular ROS were significantly increased or decreased in H9C2 cells treated with DOX after miR-140-5p mimic or miR-140-5p inhibitor transfection, respectively, as well as the changed expression levels of Nrf2 and Sirt2. Furthermore, DOX- induced myocardial oxidative damage was worsened in mice treated with miR-140-5p agomir, and however the injury was alleviated in the mice administrated with miR-140-5p antagomir. Therefore, miR-140-5p plays an important role in DOX-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Our data provide novel insights for investigating DOX-induced heart injury. In addition, miR-140-5p/ Nrf2 and miR-140-5p/Sirt2 may be the new targets to treat DOX-induced cardiotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
McGrath, J. C., & Lilley, E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12955 · Cited by 1,321
Experimental design and analysis and their reporting: new guidance for publication in BJP
Curtis, M. J., Bond, R. A., Spina, D., Ahluwalia, A., Alexander, S. P. A., Giembycz, M. A., Gilchrist, A., Hoyer, D., Insel, P. A., Izzo, A. A., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12856 · Cited by 1,033
DeSantis, C. E., Siegel, R. L., Sauer, A. G., Miller, K. D., Fedewa, S. A., Alcaraz, K. I., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21340 · Cited by 790
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Doxorubicin‐Induced Cardiotoxicity: From Bioenergetic Failure and Cell Death to Cardiomyopathy
Carvalho, F. S., Burgeiro, A., Garcia, R., Moreno, A. J., Carvalho, R. A., & Oliveira, P. J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21280 · Cited by 569
Drug-induced mitochondrial dysfunction and cardiotoxicity
Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00554.2015 · Cited by 531
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 451
The role of sirtuins in cardiac disease
Matsushima, S., & Sadoshima, J. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00053.2015 · Cited by 375
Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002661 · Cited by 334
Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms
Rochette, L., Guenancia, C., Gudjoncik, A., Hachet, O., Zeller, M., Cottin, Y., & Vergely, C. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.005 · Cited by 248
Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone
Damiani, R. M., Moura, D. J., Viau, C. M., Caceres, R. A., Henriques, J. A. P., & Saffi, J. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1759-y · Cited by 247
Autophagic dysregulation in doxorubicin cardiomyopathy
Bartlett, J. J., Trivedi, P. C., & Pulinilkunnil, T. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.01.007 · Cited by 214
New signal transduction paradigms in anthracycline-induced cardiotoxicity
Ghigo, A., Li, M., & Hirsch, E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.021 · Cited by 194
Pillai, V. B., Bindu, S., Sharp, W. W., Fang, Y. H., Kim, G. H., Gupta, M., Samant, S. A., & Gupta, M. P. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00832.2015 · Cited by 157
Breast cancer therapy-associated cardiovascular disease
Zagar, T. M., Cardinale, D. M., & Marks, L. B. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.171 · Cited by 155
Cappetta, D., Esposito, G., Piegari, E., Russo, R., Ciuffreda, L. P., Rivellino, A., Berrino, L., Rossi, F., Angelis, A. D., & Urbanek, K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.008 · Cited by 153
Yuan, Y., Ma, Z., Zhang, X., Xu, S., Zeng, X., Yang, Z., Deng, W., & Tang, Q. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.10.008 · Cited by 149
Cancer Therapy–Related Cardiac Dysfunction and Heart Failure
HAMO, C. E., Bloom, M. W., Cardinale, D. M., Ky, B., Nohria, A., Baer, L. N., Skopicki, H. A., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002843 · Cited by 144
Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Pereira, G. C., Silva, A. M., Diogo, C. V., Carvalho, F. S., Monteiro, P. F., & Oliveira, P. J. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796904812 · Cited by 136
The Role of the Nrf2/ARE Antioxidant System in Preventing Cardiovascular Diseases
Smith, R., Tran, K., Smith, C. C., McDonald, M., Shejwalkar, P., & Hara, K. (2016) · Diseases · doi:10.3390/diseases4040034 · Cited by 134
Cinnamaldehyde Prevents Endothelial Dysfunction Induced by High Glucose by Activating Nrf2
Wang, F., Pu, C., Zhou, P., Wang, P., Liang, D., Wang, Q., Hu, Y., Li, B., & Hao, X. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374074 · Cited by 130
Mitofusin 1 Is Negatively Regulated by MicroRNA 140 in Cardiomyocyte Apoptosis
Li, J., Li, Y.-Z., Jiao, J., Wang, J.-X., Li, Y.-R., Qin, D.-N., & Li, P.-F. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00774-13 · Cited by 129
Emerging Role of MicroRNAs in Cardiovascular Diseases
Rosa, S. D., Curcio, A., & Indolfi, C. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0086 · Cited by 128
Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity
Pecoraro, M., Pizzo, M. D., Marzocco, S., Sorrentino, R., Ciccarelli, M., Iaccarino, G., Pinto, A., & Popolo, A. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.01.006 · Cited by 124
Wang, J.-X., Zhang, X.-J., Feng, C., Sun, T., Wang, K., Wang, Y., Zhou, L.-Y., & Li, P.-F. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.41 · Cited by 121
The role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging
Luo, C., Urgard, E., Vooder, T., & Metspalu, A. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.04.002 · Cited by 121
Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats
Elberry, A. A., Abdel‐Naim, A. B., Abdel-Sattar, E. A., Nagy, A. A., Mosli, H. A. M., Mohamadin, A. M., & Ashour, O. M. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.02.008 · Cited by 120
Systems biology approaches to adverse drug effects: the example of cardio-oncology
Brown, S.-A. N., Sandhu, N. P., & Herrmann, J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.168 · Cited by 94
Doxorubicin in experimental and clinical heart failure
Christiansen, S., & Autschbach, R. (2006) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2006.06.024 · Cited by 86
Zordoky, B. N. M., Anwar‐Mohamed, A., Aboutabl, M. E., & El‐Kadi, A. O. S. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039123 · Cited by 85
Cardioprotective effects of sitagliptin against doxorubicin-induced cardiotoxicity in rats
El‐Agamy, D. S., Abo‐Haded, H. M., & Elkablawy, M. A. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216643418 · Cited by 85
MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction
Tony, H., Yu, K., & Qiutang, Z. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/597032 · Cited by 80
Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage
Nitiss, K. C., & Nitiss, J. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0821 · Cited by 71
Cardiomyocyte autophagy and cancer chemotherapy
Li, D. ‘., & Hill, J. A. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.007 · Cited by 69
Joshi, S. R., Dhagia, V., Gairhe, S., Edwards, J. G., McMurtry, I. F., & Gupte, S. A. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00264.2016 · Cited by 64
Boštjančič, E., Zidar, N., & Glavač, D. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-552 · Cited by 60
Sun, J., Sun, G., Cui, X.-L., Meng, X., Qin, M., & Sun, X.-D. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/6093783 · Cited by 53
Emerging role of hydrogen sulfide-microRNA crosstalk in cardiovascular diseases
Hackfort, B. T., & Mishra, P. K. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00660.2015 · Cited by 48
Yang, Y., Yu, T., Jiang, S., Zhang, Y., Li, M., Tang, N., Ponnusamy, M., Wang, J., & Li, P. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1344217 · Cited by 46
7-deacetylgedunin suppresses inflammatory responses through activation of Keap1/Nrf2/HO-1 signaling
Chen, J.-Y., Zhu, G., Su, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19017 · Cited by 42
Lopez, M., Soler, F., Sánchez‐Más, J., Pascual-Figal, D. A., Fernández-Belda, F., & Lax, A. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.02.021 · Cited by 40
Circulating microRNAs as Biomarkers in Cardiovascular Diseases
Rosa, S. D., & Indolfi, C. (2015) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-0955-9_6 · Cited by 35
Effects of crocetin on cardiotoxicity of doxorubicin in rats
Li, W., & Qian, Z. (2005) · Chinese New Drugs Journal · Cited by 3
Cited by
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Christidi, E., & Brunham, L. R. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03614-x · Cited by 684
Zhang, X., Hu, C., Kong, C.-Y., Song, P., Wu, H.-M., Xu, S.-C., Yuan, Y.-P., Deng, W., Ma, Z.-G., & Tang, Q.-Z. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0372-z · Cited by 442
Kong, C.-Y., Guo, Z., Song, P., Zhang, X., Yuan, Y.-P., Teng, T., Yan, L., & Tang, Q.-Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65258 · Cited by 412
Dissecting the Crosstalk Between Nrf2 and NF-κB Response Pathways in Drug-Induced Toxicity
Gao, W., Guo, L., Yang, Y., Wang, Y., Xia, S., Gong, H., Zhang, B.-K., & Yan, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.809952 · Cited by 320
Zhao, L., Tao, X., Qi, Y., Xu, L., Yin, L., & Peng, J. (2018) · Redox Biology · doi:10.1016/j.redox.2018.02.026 · Cited by 202
Self-citation
Metadata
- Authors
- Zhao, L., Qi, Y., Xu, L., Tao, X., Han, X., Yin, L., & Peng, J.
- Venue
- Redox Biology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 15
- Pages
- 284-296
- ISSN
- 2213-2317 (ISSN-L)
- OpenAlex
- W2778620777
- Cited by
- 344
- References
- 46
- FWCI
- 12.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.